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Abstract
Background: There is rich literature on barriers to medicines access for the treatment of non-communicable
diseases (NCDs) in high-income countries. Less is known about low- and middle-income countries, in particular the
differences in coping with medicines access barrier by household wealth and disease. The aim of this study was to
compare the coping mechanisms of patients with the lack of availability and affordability of cardio-vascular
diseases, diabetes and asthma medicines in Kenya.
Methods: This qualitative study was part of a larger mixed methods evaluation study conducted in eight counties
of Kenya from 2016 to 2019. Forty-nine patient interviews at study end line explored their NCD journey, perceptions
of availability, stockouts and affordability of NCD medicines, their enrollment in health insurance, and their
relationship with the private chemists. Transcribed interviews were coded using Nvivo software. A two-step
thematic approach was used, first conducting a priority coding which was followed by coding emerging and
divergent themes.
Results: Overall, we found that patients across all disease types and wealth level faced frequent medicine stock-
outs at health facilities. In the absence of NCD medicines at health facilities, patients coped by purchasing
medicines from local chemists, switching health facilities, requesting a different prescription, admitting oneself to an
inpatient facility, establishing connections with local staff to receive notifications of medicine stock, stocking up on
medicines, utilizing social capital to retrieve medicines from larger cities and obtaining funds from a network of
friends and family. Categorizing by disease revealed patterns in coping choices that were based on the course of
the disease, severity of the symptoms and the direct and indirect costs incurred as a result of stockouts of NCD
medicines. Categorizing by wealth highlight differences in households’ capacity to cope with the unavailability and
unaffordability of NCD medicines.
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Conclusions: The type of coping strategies to access barriers differ by NCD and wealth group. Although Kenya has
made important strides to address NCD medicines access challenges, prioritizing enrollment of low wealth
households in county health insurance programs and ensuring continuous availability of essential NCD medicines
at public health facilities close to the patient homes could improve access.
Introduction
More than 85 % of premature deaths caused by non-
communicable diseases (NCD) occur in low and middle
income countries (LMICs) [1]. NCDs can lead to lifelong
disability or premature death without adequate treat-
ment using essential medicines. Such uninterrupted pa-
tient access to essential medicines is a priority for
reducing the NCD burden in any LMIC. In Kenya, the
growing prevalence of NCDs accounts for approximately
27 % of all deaths annually [2]. Cardiovascular disease,
diabetes, and asthma are among the most prevalent
NCDs in Kenya [3, 4].
The Kenya government has made significant strides in
addressing the rising NCD burden in the country. A
number of policy interventions have been instituted to
move towards universal health coverage (UHC) at the
national and county levels [5], including national health
insurance schemes and scaling up screening, surveil-
lance, health promotion and the capacity of NCD service
delivery and referrals [6]. However, the access barriers to
NCD medicines in Kenya remain a challenge and have
been well documented [7–12]. Medicine shortages and
high prices remain the largest access barrier for patients,
despite recent policy interventions [5, 6, 10, 11, 13]. Pa-
tients from other LMICs have coped with access bar-
riers, and employed strategies such as borrowing funds,
selling assets, taking less than the prescribed dose, and
relying on social networks to borrow money for medi-
cines [7, 12, 14–19]. However, there is poor understand-
ing of the ways in which NCD patients in certain wealth
levels and those with specific diseases attempt to cope
with access barriers.
The primary aims of this study were to understand
how patients with different levels of wealth and diseases
cope with lack of availability and affordability of medi-
cines, as well as any tradeoffs made in the absence of
medicines at the household level. Evidence on patient
coping strategies can inform policy approaches to redu-
cing the burden of NCDs in Kenya.
Methods
This qualitative study was part of a larger mixed
methods evaluation conducted in eight counties in
Kenya from 2016 to 2019. The eight counties included
in the study were Embu, Kakamega, Kwale, Makueni,
Narok, Nyeri, Samburu, and West Pokot. Data were col-
lected at baseline, midline and end line. The main
purpose was to evaluate the impact of Novartis Access
Project on the availability and price of NCD medicines
included in the program portfolio and their therapeutic
equivalents [20]. The first country where the program
was roll-out was Kenya. The results of the evaluation are
reported elsewhere [21]. This study focus on the inter-
views conducted with respondents at the end line in
2019.
Sampling and selection of study participants
The sampling and selection of study participants for the
larger study have been described in detail elsewhere [20,
21]. For the purpose of this paper we will describe the
sampling that is relevant to this study: the eight study
counties were selected based on their security, safety and
volume of purchasing medicines from Mission for Es-
sential Drugs and Supplies (MEDS), an organization that
supplies medicines to a large network of public and pri-
vate (often-faith-based) health facilities. NCD services
are provided in the public and private non-profit sectors
at all levels of the health system.
A two-stage sampling procedure was used: first, ten
enumeration areas (EAs), the smallest administrative
unit in a county, were established and second, ten eli-
gible households were identified for every enumeration
area. The goal was to enroll 800 households, 100 per
county. Eligibly households had to have at least one
member 18 years or older who had previously been diag-
nosed and prescribed medicine for either diabetes,
asthma, hypertension or breast cancer. If there were
more than one member, the other adult members in the
household who met the eligibility criteria were also in-
vited to participate. For qualitative analysis, every fifth
house in an EA was eligible for an interview after com-
pletion of the quantitative surveys. At baseline where we
interviewed 84 participants. At endline we interviewed
the same participants, but due to loss to follow up we
interviewed a total of 49 out of the initial 84.
Prior to data collection during endline evaluation, a
two-day qualitative interviewing training was conducted
for all enumerators involved in data collection and man-
agement. Training was provided on human subject’s
protection, research ethics, and qualitative methods.
Semi-structured study guides were pre-tested by the
study team and developed in English. The research assis-
tants were multi-lingual and most came from the study
locations and were able to do simultaneous translation
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when necessary. The endline study questions explored
participants’ NCD journey; perceptions of availability,
stockouts and affordability of NCD medicines; partici-
pants’ enrollment in health insurance; and their relation-
ship with the private pharmacy and drug sellers. The
duration of the interviews ranged from 17 to 46 min.
Data managements and analysis
Since the study participants spoke, English or Kiswahili
and a local language that interviews were transcribed
and, when necessary, translated from Kiswahili or local
language to English. Two researchers read the typed
interview transcripts separately for accuracy and com-
pleteness. Transcripts were imported into NVivo 12
qualitative data analysis software for coding and analysis.
We used a priori coding based on the aims of (or cat-
egories related to) the evaluation, then coded for emer-
gent and divergent themes. This was followed by
constructing wealth indices and applied them across the
themes to further understand the context. The two re-
searchers did the initial coding individually and then
compared the codes of emerging themes to reach a con-
sensus, with input from and reflections with three study
authors. New codes were created, dropped and and/or
combined as appropriate. During the coding process,
data was continuously reviewed, emerging patterns
noted, and relationships between constructs and themes
identified. All codes were organized through categories
of disease (asthma, cardiovascular, diabetes plus multiple
NCDs) and household wealth level (wealth groups 1–3,
with 1 being the lowest and 3 the highest) and themes of
affordability and availability. Since there was only one
patient with diabetes, we included this patient in the
group of other patients with multiple NCDs, most of
them had diabetes plus hypertension, asthma or both.
Wealth quintiles were merged, and three wealth group
formed based on the similarities in their findings:
Wealth Group 1 corresponded with wealth quintiles 1
and 2, Wealth Group 2 corresponded with wealth quin-
tile 3 and 4, and Wealth Group 3 corresponded with
wealth quintile 5. The wealth quantiles were originally
constructed by researchers based on an asset index. Re-
searchers read and performed a selective analysis leading
to identification of salient themes.
Ethical considerations
The protocol was approved by the Institutional Review
Boards at Maseno University in.
Kenya and at Boston University Medical Center, USA.
Written informed consent was obtained for all partici-
pants at the start of the study. All participants in the
household surveys were compensated with 50 Kenyan
Shillings (USD $0.50), an amount deemed appropriate
by the local Institutional Review Boards and local
counterparts. All methods were performed in accord-
ance with the relevant guidelines and regulations.
Results
Demographic characteristics
Table 1 summarizes the sample socio-demographic
characteristics. The large majority were female, married
or living together, one fifth had no schooling and one
fifth had more than secondary school education. A larger
proportion of patients with asthma had no education
and belonged to the lowest wealth group.
The main themes that emerged from the data include:
coping mechanisms based on disease symptoms, trade-
offs, social capital and medicine management in health
systems.
Theme 1: Coping mechanisms based on diseases
symptoms
Participants within each disease category reported ex-
periencing life-threatening symptoms that required
emergency attention, and non-urgent symptoms that re-
quired attention but allowed for some delay. Respon-
dents’ sense of urgency regarding their symptoms and
proximity to accessing medicine determined their coping
strategies.
Coping with urgent symptoms
Asthma When patients with asthma were unable to get
their medicines, they described that staying without
medicines could lead to an onset of severe symptoms.
This included difficulty breathing, feelings of a congested
chest, and challenges in completing simple tasks such as
walking, standing up for short periods of time, and
working. If symptoms escalated, patients and family
caretakers felt an immediate sense of urgency to find
ways of getting the medicines. One of the options con-
sidered the fastest choice of treatment and relief was to
use emergency inpatient services or low-cost injections
for immediate symptom relief.
“I feel very bad because I can’t even breathe, I can’t
sit, I can’t even walk or to stand alone I can’t. I must
feel bad, at that time I feel bad, I wish to get the
medicine take it quickly then I feel better.” – Kaka-
mega, Asthma.
Multiple NCDs (Asthma, Diabetes, Cardiovascular
Disease) Patients who had multiple NCD’s described in-
tensified symptoms associated with lack of access to
medicines. One patient described their mother’s abrupt
hospitalization when she was unable to access medicines
briefly for two or three days, emphasizing the critical
Ng et al. BMC Health Services Research          (2021) 21:417 Page 3 of 10
impact of lack of medication access and symptom
acceleration.
“You see now my mother is sick and she needs drugs,
when there is no drug it really puts her down even
there is a day, she didn’t get the drugs until she
fainted in the house just because of failing to get the
drugs. Even the doctor… I was even carried in a ve-
hicle. She had to be admitted that day.” -Samburu,
Multiple Diseases.
Another patient with multiple NCDs explained that
even short lapses in medication could be life threat-
ening or affect the progression of any one of their
conditions.
“Because when I developed this condition, the doctor
informed me that I will have to be on medication
my entire life. Therefore, he told me that if I stop
taking medication for diabetes and as a result, the
sugar levels go up or down… sometimes it may refuse
to stabilize and you might die. For hypertension, if
you stop the medication, a spike in pressure might
result in a stroke and that might kill you. If it is
asthma, if you stop medication and get the asth-
matic attack it becomes difficult to clear. As a result,
you might be hospitalized otherwise you might die.”
-Embu, Multiple Diseases.
Coping with non‐urgent symptoms
Asthma Patients with non-urgent asthma symptoms
used various coping methods when medicines were un-
available. Several patients withheld medicine purchases,
avoided work so as to not agitate symptoms or used
traditional and herbal remedies to delay symptoms from
becoming severe. To seek medicines at the most afford-
able price, patients visited multiple public and private fa-
cilities. Some patients sent relatives to obtain medicines
or asked people living in neighboring cities to send med-
icines via mail or by car. This was particularly relevant
to asthma patients who were unable to travel long dis-
tances and were also aware of the volatility of their
health condition.
“I started using traditional remedies but that didn’t
help me because asthma is something that comes
suddenly and attacks you when you are seated and
Table 1 Sample characteristics
Total (N = 43) Hypertension (N = 23) Asthma (N = 10) Diabetes or other multiple NCDs
(N = 10)
Age 62.4 (13.9) 66.0 (14.2) 55.3 (16.4) 61.5 (7.6)
Gender:
Male 10 (23 %) 8 (35 %) 1 (10 %) 1 (11 %)
Female 33 (77 %) 15 (65 %) 9 (90 %) 9 (90 %)
Marital Status:
Single 2 (5 %) 1 (4 %) 1 (10 %) 0 (0 %)
Married or living together 29 (67 %) 18 (78 %) 5 (50 %) 6 (60 %)
Divorced or separated 1 (2 %) 0 (0 %) 0 (0 %) 1 (10 %)
Widowed 11(26 %) 4 (17 %) 4 (40 %) 3 (3 %)
Education:
Preschool (less than 1 year completed)/NONE 8 (19 %) 6 (26 %) 1 (10 %) 1 (10 %)
Primary School (not completed) 11 (26 %) 4 (17 %) 6 (60 %) 1 (10 %)
Primary school 7 (16 %) 4 (17 %) 1 (10 %) 2 (20 %)
Secondary school 10 (23 %) 6 (26 %) 1 (10 %) 3 (30 %)
Higher than secondary school 7 (16 %) 3 (13 %) 1 (10 %) 3 (30 %)
Vocational School (Post primary) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
household size - adults and children 4.3 (3.0) 4.3 (3.2) 3.9 (2.7) 5 (3.0)
Wealth Groups
Lowest 9 (21 %) 5(22 %) 4 (40 %) 0 (0 %)
Middle 20 (47 %) 14 (61 %) 3 (30 %) 3 (30 %)
Highest 14 (33 %) 4 (17 %) 3 (30 %) 7 (70 %)
Note: Continuous variables reported as mean (SD) and categorical variables reported as N (%); no household size reported for 4 households due to missing data
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makes you fall … you need something quick like an
inhaler to inhale or injection.” – Kwale, Asthma.
Cardiovascular Disease Patients with cardiovascular
disease in need of non-urgent care delayed purchasing
medicines for three to four days and sometimes up to
two weeks at a time. This allowed some patients to pur-
chase medicines in a larger city, which increased the
chances of finding medicines at a lower price. This was
an important coping strategy since patients voiced cost
burdens associated with inconsistent availability and the
progressive depletion of wealth and inability to work due
to their chronic disease management. Although patients
were able to get medicines from larger cities, they ac-
knowledged the challenges associated with using out of
pocket funds and additional indirect costs including
transportation fees and selling family assets such as live-
stock to obtain cash. Patients also struggled with how
often they could reach out to friends, family members
and relationships with staff at chemists to borrow funds
or ask for medicines on credit. Patients understood that
their chronic conditions could deplete social and monet-
ary capital over time which added a component of emo-
tional stress related to managing health while also
searching for sources of funds and the most cost-
effective medicine purchases.
“Once they miss in the hospital, you have to buy the
medicines…Somebody is advised to collect them the
next day. But the process to collect the next day, one
prefers to buy instead of wasting fare going the next
day.” -Embu, Cardiovascular Disease.
Multiple NCDs Under non-urgent circumstances, pa-
tients with multiple NCDs voiced the significant finan-
cial burdens associated with purchasing multiple
medications to treat their NCDs. Therefore, to make the
most economic choice, patients preferred to visit public
health facilities and use insurance as their primary mode
of payment. Patients felt that delaying medicine pur-
chases was worthwhile to maximize insurance benefits
and avoid out of pocket costs. Under non-urgent symp-
toms, patients regularly went to public health facilities to
get tested for blood pressure and sugar levels. The fre-
quency at which patients monitored health conditions
determined opportunities to look for and receive medi-
cines and potentially influenced the perception of avail-
ability at health facilities. In the face of unavailability,
patients searched for medicines in private facilities and
voiced that price was of utmost concern. This resulted
in patients searching for medicines in locations with
multiple chemists at different price points.
Theme 2: Wealth and tradeoffs to overcome barriers of
access to NCD medicines
Respondents with NCDs across the three wealth levels
coped with frequent medicine stock outs in the public
facilities by purchasing from chemists or private facil-
ities. In order to afford NCD medicines from the private
sector, household members described a range of trade-
offs, such as: forgoing essential items, selling assets, and
spending their savings. Households, regardless of wealth
group, described significant tradeoffs in order to afford
medicine. However, poorer households in groups 1 and
2 frequently reported larger sacrifices, such as forgoing
basic food or depleting household assets, compared to
their counterparts in wealth group 3, where these trade-
offs were less common.
Forgoing essential items
Respondents across all wealth levels reported forgoing
essential items in order to cover the cost of NCD medi-
cines. Items deemed essential were relative to their
wealth group, all of which had implications for the
household livelihoods. For example, the lowest wealth
level frequently reported items such as food, hygiene
products, and clothing:
“sometimes you might go with your program, you
find something is missing you say better I miss food
today I get this, I better lack this cloth I get this one”
-Narok, Wealth Group 1.
“Sometimes even when I don’t have bathing soap
and I don’t have money I forego buying soap so that
I can buy medicine.”—Embu, Wealth Group 1.
Some households in the second level wealth group de-
scribed frequently forgoing certain types of food, and
most described items such as sugar, school fees, and
clothing.
“That whole year, we have had to stay without using
the basics, you are forced to forgo one thing to be
able to get the drugs. Like if you were to buy beans,
you are forced to cook food without beans”–Nyeri,
Wealth Group 2.
“It has taken us backward so much, we don’t pay
school fees and the issue is the chest, and food you
also deny yourselves you don’t buy because first there
is the drugs.” –Kwale, Wealth Group 2.
Households in the upper wealth group mentioned for-
going items with less frequency than wealth groups 1–2,
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however clothing, school fees, ice cream, meat, and
petrol were all identified.
“before, we used to use things like ice cream but right
now, we cannot…We used to eat chicken, now we do
not,…What really affected us most is movement by
use of a vehicle…Petrol is expensive therefore, we de-
cided instead of moving, let us set aside the money.
So we took our money to buy to drugs.”—Embu,
Wealth Group 3.
Reduction in wealth and assets
Respondents at all wealth levels list selling a range of as-
sets in order to cover the cost of their NCD medicine;
chickens, goats, and land were sold at various times.
Households in the mid- and lower-wealth groups fre-
quently reported selling assets in order to cover the cost
of NCD medicine; whereas this coping mechanism ap-
peared with less frequency in households in the upper
wealth group.
“I have to sell the chicken cheaply so that I can get
medicines, rearing chicken you can only do that if
you are not sick and are focused, if you have the
chicken you will sell it so you can buy a goat but if I
am sick I am not able to buy the goat but buy the
medicines.” –Embu, Wealth Group 1.
“Wealth has decreased, truly wealth has decreased
because of the way the illness affects mother, we need
to sell our wealth, to use a lot of money and even go
into debts because of her condition.”—Samburu,
Wealth Group 2.
“Yes, I had a car and I sold. I had a cow and I sold.
So I have got just one cow and two calves.”—Nyeri,
Wealth Group 3.
Theme 3: Using social capital for financial and social
support
Social capital has been defined as “the informal and or-
ganized reciprocal networks of trust and norms embed-
ded in social organization of communities –with social
institutions both hierarchical and horizontal in struc-
ture” [22, 23]. The respondents relied on their social
capital through connections with friends, relatives and
co-workers to access NCD medicines, ranging from bor-
rowing funds, purchasing medicines on credit, or being
granted reduced prices. However, households at the low-
est wealth levels had less leverage to lean on social net-
works to gain access to NCD medicines. Their social
networks were unable to provide comparative financial
or social support in accessing medicine as compared to
households in the mid-and highest wealth group. The
following sub-themes explore the relationship between
social capital and wealth quintile.
Borrowing money & assets
Households from the lowest wealth group frequently
described trying to borrow money from their social
networks, often without success. They were expected
to repay the debt, which added an additional financial
burden in addition to regular payments for NCD
medicine. For those in the lowest wealth group, bor-
rowing money could lead to impoverishment because
households had to consistently pay debts, making it
difficult to save or invest meaningfully. Respondents
in the middle and highest wealth groups frequently
received financial assistance from their children with-
out problem.
“I usually feel bad because…I usually don’t have
money, so when they tell me to go buy I…I have to
start thinking of going to [mentions a name] so that
I can borrow money to buy this drug so that I don’t
go disturb people at home, so I just go somewhere
and borrow so that even if I get one packet so that I
can go back with it at home.” -Embu, Wealth Group
1.
This financial assistance may be a relief for patients
but may have implications on their children’s wealth,
resulting in an intergenerational depletion of household
wealth and assets.
“Initially, like now we have livestock, goats there are
times mother is so ill that we are forced to sell a goat
to be able to cater for her medication. If my brother
doesn’t have money here we are forced to send a goat
to be sold to reduce the bill, sometimes mother has
money in her account we go into the mothers ac-
count and withdraw some money just for the illness.
This disease has made mother to spend her more
than usual.” –Samburu, Wealth Group 2.
Personal relationships with chemist/facility staff
Respondents in the middle and highest wealth group
also reported that their professional or personal connec-
tions to chemist and facility staff facilitated their ability
to access NCD medicines at reduced or free prices. Very
few examples of this were found during interviews with
patients in the lowest wealth group.
“…there is a drug for her for asthma that she nor-
mally has, now if you go, there is a chemist around
here and she and my mother know each other so she
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will just give you, she will sell it to you cheaply and
not expensive.” Samburu, Wealth Group 3.
Alternative payment structure
Multiple patients described being granted flexibility in
payment structure. It was not clear if this was due to the
patient’s personal relationship to staff at the facility, or if
it is simply facility policy and that these patients know
where to go, in order to obtain such flexibility. Regard-
less, these types of experiences were often described in
the lowest wealth groups.
“when we go there and we don’t have money, we tell
them we will pay later they trust us we will pay
when we get money.” -Samburu, Wealth Group 2.
Theme 4: Health insurance does not guarantee access to
NCD medicines
One salient challenge patients mentioned was the execu-
tion of the National Hospital Insurance Fund (NHIF).
No patients in lowest wealth group used health insur-
ance to help pay for medicine, whereas patients in the
middle and upper wealth group frequently reported
using health insurance.
Some patients required multiple medicines and pur-
chased NHIF insurance to offset monthly costs. How-
ever, the value of the NHIF was questioned when
patients arrived at the public facility to find their
medicines unavailable. Often described as a “double-
cost,” patients who purchased health insurance
expressed their frustration paying for medicines at
private facilities because the public facilities were out
of stock.
“[Y]ou are disappointed, you just see how you have
wasted money and then there is no drug, you will be
forced again to buy it which is a double cost.” -Kaka-
mega, Cardiovascular Disease.
There were exceptions where patients felt that NHIF
had assisted in the purchase of medicines. Some patients
observed increased access to free blood pressure and
diabetes medications, compared to previous years where
only half of prescribed medications were available. Ul-
timately, many patients accepted their health circum-
stances and the unavailability of medicines, and planned
for necessary funds to afford both direct and indirect
costs.
“I know that I use fifteen thousand per month on
drugs …therefore, if I find them at …I am grate-
ful. And, if they are unavailable, I keep the
money knowing that next month… all that is be-
cause of uncertainty of whether the drugs will be
available or not. I, however, make sure that I
have the money…” - Embu, Multiple NCDs.
Discussion
This paper has illuminated how patients cope with the
lack of availability and affordability of NCD medicines at
the household level, categorized by disease and wealth
level in eight counties in Kenya. Regardless of wealth
level and disease type, most patients struggled with fre-
quent medicine stockouts at health facilities, which
forced patients to turn to the private sector in order to
procure NCD medicines. The price of NCD medicines
and opportunity costs were the greatest barriers to
accessing medicines from chemists and other private fa-
cilities. Households made significant tradeoffs in order
to cope with the high prices of medicines, often resulting
in the depletion of household wealth over time. These
findings suggest that NCD medicine availability and af-
fordability remain an ongoing issue ([24].
Our study contributes to knowledge on the experi-
ences and opinions of patients on how they cope with
access to NCD medicines. Although strategies such as
borrowing funds, forgoing essential items, selling off
assets, and relying on social networks to procure
medicines have all been documented in other studies
[7, 10–12].
Our study provides insights into coping with a lack of
availability and unaffordability of NCD medicines across
three prevalent NCDs and wealth levels.
Firstly, coping with unavailability and unaffordability
of NCD medicines varied among patients depending on
the disease. Differences in disease progression and symp-
tom manifestations suggest a temporal component that
determine coping strategies and economic pathways.
Secondly, while the findings are consistent with existing
literature that NCD medicines pose a significant finan-
cial burden to Kenyan households [7–9] they add a note-
worthy nuance: while all wealth levels made substantial
tradeoffs in order to access NCD medicines, the trade-
offs made by households within lower wealth levels had
long term repercussions on household wealth and stabil-
ity. Coping with the high cost of NCD medicine by sell-
ing certain assets precipitated a cascade of additional
financial burdens or loss of livelihoods. For example, one
of the most common liquidated assets mentioned was
livestock. In addition to providing useful commodities,
such as eggs, milk, or meat that the families may depend
on for daily living, livestock represent an investment in
future wealth and earnings. Selling these can lead to sig-
nificant loss of livelihoods in the long-term and contrib-
ute to intergenerational poverty.
Thirdly, although similar studies have found that pa-
tients rely on social networks to facilitate medicine ac-
cess [7, 10], our results show that the leverage offered by
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these networks was different across wealth categories.
Households from lower wealth levels were less likely to
rely on access social networks for financial support, re-
duced prices, or notifications of medicine stocks. People
in the middle and upper wealth levels were able to use
their social capital to establish relationships and trust
with private chemist and health facility staff, which fur-
ther rewarded their access to NCD medicine.
Finally, the introduction of a national insurance system
has been traditionally viewed as a financial asset to NCD
patients (Kankeu et al., 2013). We found that patients
with cardiovascular disease and multiple NCDs with
multiple medicines relied on the insurance system as a
means to offset high monthly medication costs. How-
ever, inconsistent public sector supply resulted in pa-
tients not receiving medicines free of charge at the point
of care even though they were included in the insurance
benefit package. Patients therefore, faced a double finan-
cial burden of paying for health insurance premiums
plus their monthly medicines. Scaling up the roll-out of
health insurance will require reliable public sector sup-
ply of medicines that are included in the insurance bene-
fit package in order to protect patients from financial
expenses on medicines.
Study limitations
There were some limitations to these findings. The ori-
ginal study design addressed questions regarding the im-
pact of the Novartis Access programs on the availability
and affordability of NCD medicines. Categorizing by dis-
ease and wealth group was part of a secondary analysis
which limits the generalizability of the results. Future
studies could consider the number and types of individ-
uals that patients rely on within social networks for as-
sistance. Additional research questions related to disease
progression could clarify the progression and long-term
impact of medicine access programs. Additionally, sam-
pling across wealth and disease groups could ensure that
the results are representative of the specific populations
of interest.
Recommendations
Across all disease types, patients voiced the additional
costs and burdens of searching within public and private
facilities for medicines. Public and private facilities facing
inconsistent medicine supply could benefit from a trans-
parent supply chain system where stock level informa-
tion is made public to patients, health providers, and
administrators via SMS or other available mobile tech-
nologies. Such a system would notify patients about
medicine stock prior to traveling to the facility, saving
patients the experience of spending resources and time
on travel to find medicines unavailable. Other strategies
to promote transparency could include top down
methods of information access, where clinicians and
or community health workers (CHW) regularly visit
NCD households to provide support, education and
information about available supplies. NCD care stud-
ies using CHW show the benefits of this direct
access, and how this model could address NCD
education and holistic aspects of health in addition to
NCD medicine access [25].
Additional studies have addressed expansion of insur-
ance programs to cover the cost of medicines at private
facilities as well as low enrollment rates amongst rural
communities within Kenya [12, 26]. Currently, private
chemists do not accept insurance, which can serve to in-
crease cost barriers to accessing NCD medicines [27].
Expanding insurance coverage and reimbursements
within private facilities could reduce financial burdens
and minimize the indirect costs associated with incon-
sistent supplies at public facilities. Our results also sug-
gest that patients of lowest wealth group did not utilize
insurance as often as highest wealth group. Therefore,
the implementation of insurance programs must target
the lowest wealth groups. Insurance should be expanded
in parallel to the improvement of medicine supply
chains, and insurance coverage across public and private
facilities.
Our findings from wealth groups suggest that individ-
uals who possess a larger social network and existing fi-
nancial assets are better positioned to cope with NCD
medicine management. Individuals who reached out to
family members and owned larger financial assets typic-
ally could withstand the long-term financial costs of
medicines. Therefore, strengthening social networks
could specifically prioritize low income patients. Future
economic studies of household assets sold to purchase
medicines, the expenditure on medicines and its impact
on impoverishment would be valuable.
Lastly, the theme of emotional stress related to chronic
disease management surfaced throughout the interviews.
While this was not the focus of this study, this area war-
rants further exploration, taking into consideration a
more expansive definition of health such as the WHO’s
which incorporates the concept of overall wellbeing into
its definition of health [28]. This is particularly, among
patients diagnosed with cardiovascular disease and mul-
tiple NCDs diagnosed at an early stage of life. These pa-
tients voiced the emotional toll related to procuring
NCD medicines and the subsequent impact on self-
identity and community engagement. And lastly, longi-
tudinal studies could illuminate the progression of social
and financial impact of NCD medicine access.
Conclusions
The type of coping strategies to access barriers differed
by non-communicable disease and wealth group.
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Although Kenya has made important steps to address
access to NCD medicines challenges, prioritizing enroll-
ment of low wealth households in county health insur-
ance programs and ensuring continuous availability of
essential NCD medicines at public health facilities close
to the patient homes could significantly improve access.
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